At least, Reuters has it this way -- if it holds up, this is a major shift -- in record time. And, it seems, AstraZeneca is taking this share from Schering's Vytorin/Zetia cholesterol franchise, among others -- will Vytorin/Zetia fall below 10 percent share (before Year-End 2008)? I now think so, and perhaps even sooner:
. . . .Crestor's share of the U.S. statin drug market in terms of new prescriptions rose to 10.7 percent in the week ended Nov. 14, up from 10.1 percent a week earlier, according to figures compiled by IMS Health and cited by several brokerages.
Its total prescription share rose to 9.8 percent from 9.5 percent. . . .
No comments:
Post a Comment